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Results: After 52 cycles administered, pts received a median of 2 
cycles of treatment (1-6). All patients except one were considered 
evaluable for toxicity, with the recording of ﬁve episodes of (22%) nau-
sea/vomiting grade 1-2 and one (4%) of asthenia grade 1. Four (17%) 
patients developed anaemia grade 2-3 and neutropenia grade1. Two 
additional patients (9%) had neutropenia grade 2 and one (4%) grade 
V. Among twenty evaluable pts for activity, one (4%) showed partial 
response, seven (29%) stable disease and twelve (50%) progression dis-
ease. Median time to progression and overall survival are 54 (12-210) 
and 60 (12-485) days respectively.
Conclusion: At this time of evaluation, intravenous Topotecan with 
this schedule and dose shows promising activity. The accrual still 
continues until the planned sample size following the Simon Two-stage 
design.
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Taxotere as salvage chemotherapy in Chinese patients with 
advanced NSCLC who have failed or relapsed after the gefitinib 
target treatment
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Background: This Phase II study was conducted to evaluate the ef-
ﬁcacy and toxicity of docetaxel single agent in salvage therapy for 
patients with advanced non-small cell lung cancer (NSCLC) who failed 
to respond or relapsed after the geﬁtinib. 
Methods: Patients with histologically conﬁrmed and progressive 
NSCLC after geﬁtinib were eligible for this study. Performance status 
of 0-1 and adequate organ function were required. Patients were treated 
with docetaxel 75 mg/m(2) intravenously for 30 min repeated every 3 
weeks until disease progression or intolerant toxicity. 
Results: Twenty patients were eligible for this study. The TTP for 
iressa was 12 months. Average 2.9 cycles taxotere were given. Hema-
tologic toxicity was mild and with the major toxicity of anemia and 
peripheral neuropathy. The overall response rate (ORR) was 15% and 
disease control rate was 40%. The median survival time (MST) for all 
patients was 542 days (95% CI, 238.2-845.7), TTP was 3.5 months and 
the 1 year survival was 50.2%. 
Conclusions: Docetaxel appeared to be well tolerated as salvage 
therapy for patients with NSCLC who failed to geﬁitinib. 
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Marked response to a cisplatin/docetaxel/temozolomide 
combination in a heavily pre-treated lung cancer patient with a 
metastatic large cell neuroendocrine tumour.
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Introduction: Large cell neuroendocrine carcinoma (LCNEC) is rare 
and differs from other non-small cell lung carcinomas (NSCLC) in that 
it has a particularly aggressive clinical behaviour with poor prognosis. 
We report a dramatic response in body and brain metastases in a heav-
ily pre-treated LCNEC patient receiving a fourth-line combination of 
cisplatin / docetaxel / temozolomide. 
Case Report: A 52-year-old female initially presented with increasing 
breathlessness and superior vena cava obstruction. Histology showed 
LCNEC. Computed tomography showed bulky mediastinal disease. 
Over the next 6 months she received two lines of chemotherapy [cis-
platin / etoposide (stable disease), followed by carboplatin / paclitaxel 
/ radiotherapy (good partial response)]. She progressed 8 months from 
diagnosis with brain metastases (one 5cm diameter). She had a partial 
response to whole brain radiotherapy, but soon after completion she 
was commenced on geﬁtinib for progressive intraabdominal disease. 
She progressed on geﬁtinib with marked clinical deterioration and mas-
sive radiological progression in mediastinum, liver, adrenal and brain 
(12 months from presentation). After a request for more treatment a cis-
platin, docetaxel and temozolomide triplet combination was adminis-
tered [cisplatin 40mg/m2 iv day 1; docetaxel 25 mg/m2 iv days 1, 8, 15; 
temozolomide 150mg/m2 orally days 1-5, every 4 weeks]. The regimen 
was based on a single previous case report in metastatic NSCLC and 
the patient received four cycles of treatment. An excellent symptomatic 
and radiological response (including the brain metastases) was seen, 
with a marked improvement in her quality of life that enabled her to re-
turn to full activity. Unfortunately the disease started to progress again 
four months later and the patient died 20 months from presentation.
Discussion: LCNEC is a rare tumour. The tumour is traditionally 
considered to fall within the category of poorly differentiated NSCLC. 
However, outcomes are similar to SCLC, including a propensity for 
early brain metastases. This is the second report in the literature on the 
use of this speciﬁc chemotherapy combination in NSCLC and the ﬁrst 
report of this cisplatin / docetaxel / temozolomide regimen in LCNEC. 
This triplet is a well-tolerated novel outpatient combination chemother-
apy regimen that treats both systemic and intracranial disease. 
The growing evidence form case series and phase II trials on the use 
of temozolomide containing regimens in patients with reccurent or 
progressive brain metastases from solid tumours will be reviewed. In 
patients who have failed WBRT palliative care was usually the only 
available management option. For ﬁt patients temozolomide singly or 
preferably in combination may offer a real alternative. 
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Efficacy of cisplatin and vinorelbine in patients with metastatic 
NSCLC
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Background: Chemotherapy for advanced NSCLC has gained 
widespread acceptance since it was demonstrated that cisplatin-based 
chemotherapy improved survival and quality of life.The aim of this 
study is to evaluate the feasibility in terms of overall survival, response 
rate and toxicity of the cisplatin-vinorelbine in Turkish patients with 
metastatic NSCLC.
Methods: In this prospective study, ECOG performance 0-1, che-
motherapy-naive stage IV NSCLC patients (pts) were treated with 
cisplatin (75 mg/m2, d1, IV) and vinorelbine (30 mg/m2, d1and d8, IV) 
every 21 days until progesion or unacceptable toxicity for a maximum 
of 6 cycles in single center. Tumor responses were evaluated by WHO 
criteia. Survival was calculated with the Kaplan-Meier method. Eight 
